Form 4: Immix Biopharma Director Helen C. Adams Acquires Stock Options

Director Helen C. Adams reports acquisition of stock options in Immix Biopharma, Inc.

Summary

• Helen C. Adams, a director of Immix Biopharma, Inc. [IMMX], filed a Form 4 on June 21, 2024, reporting a transaction.
• On June 11, 2024, Adams acquired stock options to purchase 33,000 shares of common stock at an exercise price of $2.04.
• The options vest in twelve equal monthly installments, contingent upon continued service on the Board of Directors, and expire on June 11, 2034.
• Following the transaction, Adams directly owns 174,754 shares of common stock and holds options for 33,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock option grants, which doesn't inherently indicate positive or negative sentiment but suggests alignment of interests.

Positives

• The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Monitoring such filings can provide insights into management's sentiment and alignment with shareholder interests.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment, as it suggests confidence in the company's future.

Key Dates